Navigation Links
CoAxia Announces Results of SENTIS Ischemic Stroke Trial
Date:10/18/2010

MINNEAPOLIS, Oct. 18 /PRNewswire/ -- CoAxia Inc. of Maple Grove, MN, announced today that the results of the SENTIS clinical trial - a worldwide, multi-center, randomized study of its NeuroFlo™ catheter – were presented on Saturday, October 16th, by SENTIS Principal Investigator, Professor Ashfaq Shuaib at the 2010 World Stroke Congress in Seoul, South Korea.  Professor Shuaib noted that SENTIS is the first randomized trial of an acute interventional treatment in ischemic stroke patients to signal safety and long term improvement in clinical outcomes.  CoAxia is developing plans to submit trial results to the US FDA and exploring options to initiate marketing of the NeuroFlo technology in Europe, where it has previously received CE Mark.

Professor Shuaib, Director of Stroke Services, University of Edmonton Medical Center, described the SENTIS trial results as follows: whereas the NeuroFlo treatment did not achieve statistical significance in its primary efficacy measure, it did achieve the trial's primary safety endpoint and demonstrated numerous positive indications of both safety and benefit.  He presented positive safety results in overall mortality and stroke-related mortality, and improved neurological outcomes, as measured by 90 day modified Rankin 0-2 scores, in early-presenting patients, mid-range stroke patients, and patients over 70 years of age.

The SENTIS trial included patients presenting with strokes up to 14 hours after symptom onset with baseline stroke severity NIHSS scores between 5 and 18.  Patients were randomized 1:1 to either NeuroFlo treatment or standard medical care.  Patients eligible for either intra-venous tPA (approximately 2-3% of stoke patients) or intra-arterial clot removal (< 1% of stroke patients) were excluded from the trial.  The SENTIS endpoints included a range of neurological efficacy and safety measures assessed 90 days after symptom onset.  These measures inc
'/>"/>

SOURCE CoAxia, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CoAxia(TM) Announces $11.5M Equity Financing From Existing Investors
2. CoAxia, Inc. Announces $21.5M Series D Financing
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Mass. , Aug. 28, 2014  Decision Resources Group ... remain constant, at around $7.7 billion by 2023 in ... , Germany , Italy ... Kingdom and Japan . The ... Erbitux will be balanced out by the launch of Eli ...
(Date:8/28/2014)... YORK , Aug. 28, 2014 Levi ... been commenced in the United States District Court for ... behalf of investors who purchased Galectin Therapeutics Inc. ("Galectin" ... 2014 and July 28, 2014. For more ... complaint alleges that during the Class Period the Company ...
(Date:8/28/2014)... 28, 2014 Nonin Medical, Inc., the inventor ... medical monitoring, today announced that the Food and Drug ... finger pulse oximeter for use in the ... into a telemedicine hub or kiosk through a USB ... pediatric to adult patients. The Model 3231 received EU ...
Breaking Medicine Technology:The Colorectal Cancer Market Will Remain Steady at $7.7 Billion by 2023, With Biosimilar Erosion Of Key Agents Being Balanced Out By the Launch Of Premium-Priced Therapies 2SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Galectin Therapeutics Inc. and Its Board of Directors and a Lead Plaintiff Deadline of September 29, 2014 -- GALT 2Nonin Medical Announces FDA Clearance of Nonin Model 3231 USB Pulse Oximeter 2
... 2012 Reportlinker.com announces that a ... in its catalogue: , ... Report & Forecast: 2011-2016 ... in antibody technology has revolutionized both ...
... Texas, Feb. 6, 2012 Luminex Corporation (NASDAQ: ... fourth quarter and year ended December 31, 2011.  Financial ... (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) Consolidated fourth quarter ... over the fourth quarter of 2010; full-year 2011 revenue ...
Cached Medicine Technology:Indian Diagnostic & Therapeutic Antibodies Market Report & Forecast: 2011-2016 2Indian Diagnostic & Therapeutic Antibodies Market Report & Forecast: 2011-2016 3Indian Diagnostic & Therapeutic Antibodies Market Report & Forecast: 2011-2016 4Indian Diagnostic & Therapeutic Antibodies Market Report & Forecast: 2011-2016 5Indian Diagnostic & Therapeutic Antibodies Market Report & Forecast: 2011-2016 6Indian Diagnostic & Therapeutic Antibodies Market Report & Forecast: 2011-2016 7Luminex Corporation Reports Fourth Quarter and Full Year 2011 Results 2Luminex Corporation Reports Fourth Quarter and Full Year 2011 Results 3Luminex Corporation Reports Fourth Quarter and Full Year 2011 Results 4Luminex Corporation Reports Fourth Quarter and Full Year 2011 Results 5Luminex Corporation Reports Fourth Quarter and Full Year 2011 Results 6Luminex Corporation Reports Fourth Quarter and Full Year 2011 Results 7Luminex Corporation Reports Fourth Quarter and Full Year 2011 Results 8Luminex Corporation Reports Fourth Quarter and Full Year 2011 Results 9
(Date:8/28/2014)... Steven Reinberg HealthDay Reporter ... salt in the diet may worsen symptoms of multiple sclerosis ... factors affect MS, such as vitamin D, smoking and Epstein ... may be another environmental factor affecting MS patients," said lead ... Neurological Research in Buenos Aires. Multiple sclerosis is a ...
(Date:8/28/2014)... 28, 2014 ABC television stars will ... MDA Show of Strength Telethon airing Sunday, Aug. 31, ... help raise funds and awareness to help save and ... muscle disease. , Viewers tuning into the 2014 telethon ... appeals and introductions from some of the network’s leading ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 Biotronic, a ... leading intraoperative neurophysiology monitoring ("IONM") company, today announced the ... position of Chief Executive Officer effective immediately. Mr. Gecsey ... President and CFO in 2013 and has been an ... , “Bill’s efforts and achievements since joining the company ...
(Date:8/28/2014)... 28, 2014 Allegheny Health ... a regional partnership designed to advance sports nutrition ... competitive young athletes, scholastic athletes and their families ... Body & Mind Initiative will offer a comprehensive ... physical and mental dynamics involved in pursuing athletic ...
(Date:8/28/2014)... 28, 2014 Valero Renewable Fuels Company, ... (NYSE: VLO), and the Ports of Indiana hosted Lt. ... today at a Port Appreciation and Welcome Celebration commemorating ... plant. , “The opening of Valero’s ethanol facility at ... economic development win for the State of Indiana,” Ellspermann ...
Breaking Medicine News(10 mins):Health News:Could Too Much Salt Harm MS Patients? 2Health News:Could Too Much Salt Harm MS Patients? 3Health News:ABC Stars Unite to Fight Back Against Muscle Disease During MDA Show of Strength Telethon 2Health News:ABC Stars Unite to Fight Back Against Muscle Disease During MDA Show of Strength Telethon 3Health News:ABC Stars Unite to Fight Back Against Muscle Disease During MDA Show of Strength Telethon 4Health News:Biotronic NeuroNetwork Announces the Promotion of Bill Gecsey to CEO 2Health News:Allegheny Health Network and Come Ready Nutrition Announce Regional Partnership 2Health News:Allegheny Health Network and Come Ready Nutrition Announce Regional Partnership 3Health News:Allegheny Health Network and Come Ready Nutrition Announce Regional Partnership 4Health News:Valero, Ports of Indiana Celebrate Restart of Ethanol Plant 2Health News:Valero, Ports of Indiana Celebrate Restart of Ethanol Plant 3
... WASHINGTON, Nov. 8 Speaker Nancy Pelosi and Democratic leaders held ... Affordable Health Care for America Act. The bill passed by ... opening remarks: , "I and some of my colleagues just ... Obama, congratulating us on a great victory for the American people. ...
... ... Company’s Mississauga, Ontario facility. , ... Toronto, ON (PRWEB) November 8, 2009 -- Thomas Wellner, President and ... a commercial scale pharmaceutical grade freeze dryer and expects to make commercial scale freeze ...
... does not mean the battle is won," said Dr. Charmaine ... of 240-194, the Stupak-Ellsworth-Pitts-Kaptur-Dahlkemper-Lipinski-Smith Amendment to prohibit abortion mandates and ... Americans United for Life Action President and CEO Dr. Charmaine ... for the pro-life Americans across this country who have flooded ...
... of H.R. 3961 to Secure the Stability of Medicare ... Rohack, M.D., President, American Medical Association. , (Logo: ... of the House health reform bill, which will help improve ... swift passage of H.R. 3961 to secure the stability of ...
... Care Reform Bill , Critical legislation would ... BALTIMORE, Nov. 7 SUMMARY: Tonight the ... reform legislation that would strengthen Medicare for seniors and ... Americans out of affordable health coverage. , The Affordable ...
... The American Medical Association (AMA) today awarded its 2009 Benjamin ... Kraff, M.D., an ophthalmologist from Chicago, IL. The award recognizes ... of duty to make an outstanding public service contribution to ... the opening session of the 2009 Interim Meeting of the ...
Cached Medicine News:Health News:Therapure Biopharma Inc. Announces Delivery of its First Commercial-Scale Lyophilizer 2Health News:Americans United for Life Action Comments on Passage of Pro-Life Amendment: Bipartisan Pro-life Majority Reflects the Will of the American People 2Health News:AMA Hails House Passage of Health Reform Bill (H.R. 3962) 2Health News:AARP Maryland Key Vote News Alert 2Health News:AARP Maryland Key Vote News Alert 3Health News:AMA Honors IL Ophthalmologist Manus C. Kraff M.D. for Volunteer Eye Care for Military Members 2
96 channel Parallel dispenser using Positive Air Displacement Technology...
The WellPro 384 is designed for use with 384 well microplates. It utilizes a 24 channel liquid head and can perform serial dilutions in a 16 or 24 across format, and plate to plate transfers and plat...
The WP1000S is a shortened base version of the WellPro that is shortened 5 inches to facilitate fitting into smaller biohazard hoods....
... The Labcyte Echo 550 compound ... droplets down to 5 nL using ... on focused acoustic energy. Monitoring of ... fluids enables the Echo 550 to ...
Medicine Products: